Eledon Pharmaceuticals Management
Management criteria checks 2/4
Eledon Pharmaceuticals' CEO is DA Gros, appointed in Sep 2020, has a tenure of 4.17 years. total yearly compensation is $2.55M, comprised of 21.9% salary and 78.1% bonuses, including company stock and options. directly owns 0.015% of the company’s shares, worth €36.21K. The average tenure of the management team and the board of directors is 3.6 years and 5.9 years respectively.
Key information
DA Gros
Chief executive officer
US$2.6m
Total compensation
| CEO salary percentage | 21.9% |
| CEO tenure | 4.2yrs |
| CEO ownership | 0.02% |
| Management average tenure | 3.6yrs |
| Board average tenure | 5.9yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$25m |
| Jun 30 2024 | n/a | n/a | -US$89m |
| Mar 31 2024 | n/a | n/a | -US$129m |
| Dec 31 2023 | US$3m | US$559k | -US$117m |
| Sep 30 2023 | n/a | n/a | -US$145m |
| Jun 30 2023 | n/a | n/a | -US$145m |
| Mar 31 2023 | n/a | n/a | -US$89m |
| Dec 31 2022 | US$1m | US$533k | -US$88m |
| Sep 30 2022 | n/a | n/a | -US$38m |
| Jun 30 2022 | n/a | n/a | -US$38m |
| Mar 31 2022 | n/a | n/a | -US$36m |
| Dec 31 2021 | US$748k | US$504k | -US$35m |
| Sep 30 2021 | n/a | n/a | -US$32m |
| Jun 30 2021 | n/a | n/a | -US$28m |
| Mar 31 2021 | n/a | n/a | -US$23m |
| Dec 31 2020 | US$7m | US$150k | -US$23m |
Compensation vs Market: DA's total compensation ($USD2.55M) is above average for companies of similar size in the German market ($USD787.21K).
Compensation vs Earnings: DA's compensation has increased whilst the company is unprofitable.
CEO
DA Gros (52 yo)
4.2yrs
Tenure
US$2,553,153
Compensation
Dr. David-Alexandre C. Gros, also known as DA, M.D., Ph D., serves as Chief Executive Officer and Non-Independent Director at Eledon Pharmaceuticals, Inc. since September 09, 2020. Dr. Gros served as an ad...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Non Independent Director | 4.2yrs | US$2.55m | 0.015% € 36.2k | |
| President | 4.2yrs | US$1.54m | 0.0017% € 4.0k | |
| Chief Financial Officer | 3.7yrs | US$1.32m | 0.017% € 40.2k | |
| Vice President of Technical Operations | 2.5yrs | no data | no data | |
| General Counsel | 3.6yrs | US$1.68m | 0% € 0 | |
| Chief Regulatory Officer | 3.6yrs | no data | no data | |
| Chief Medical Officer | 1.1yrs | no data | no data |
3.6yrs
Average Tenure
55yo
Average Age
Experienced Management: 2TK's management team is considered experienced (3.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Non Independent Director | 4.2yrs | US$2.55m | 0.015% € 36.2k | |
| President | 4.2yrs | US$1.54m | 0.0017% € 4.0k | |
| Independent Chairman of the Board | 7.5yrs | US$1.52m | 0.0011% € 2.7k | |
| Independent Director | 7.5yrs | US$371.82k | 0% € 0 | |
| Independent Director | 1.1yrs | US$201.79k | no data | |
| Independent Director | 3.9yrs | US$374.44k | 0% € 0 | |
| Member of Scientific Advisory Board | 5.9yrs | no data | no data | |
| Member of Scientific Advisory Board | 5.9yrs | no data | no data | |
| Member of Scientific Advisory Board | 5.9yrs | no data | no data | |
| Member of Scientific Advisory Board | 5.9yrs | no data | no data | |
| Member of Scientific Advisory Board | 5.9yrs | no data | no data | |
| Member of Scientific Advisory Board | 5.9yrs | no data | no data |
5.9yrs
Average Tenure
56yo
Average Age
Experienced Board: 2TK's board of directors are considered experienced (5.9 years average tenure).